首页> 外文OA文献 >Efficient Serum Clearance of Botulinum Neurotoxin Achieved Using a Pool of Small Antitoxin Binding Agents▿
【2h】

Efficient Serum Clearance of Botulinum Neurotoxin Achieved Using a Pool of Small Antitoxin Binding Agents▿

机译:使用少量抗毒素结合剂可有效清除肉毒杆菌神经毒素的血清

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Antitoxins for botulinum neurotoxins (BoNTs) and other toxins are needed that can be produced economically with improved safety and shelf-life properties compared to conventional therapeutics with large-animal antisera. Here we show that protection from BoNT lethality and rapid BoNT clearance through the liver can be elicited in mice by administration of a pool of epitope-tagged small protein binding agents together with a single anti-tag monoclonal antibody (MAb). The protein binding agents used in this study were single-chain Fv domains (scFvs) with high affinity for BoNT serotype A (BoNT/A). The addition of increasing numbers of differently tagged scFvs synergistically increased the level of protection against BoNT/A. It was not necessary that any of the BoNT/A binding agents possess toxin-neutralizing activity. Mice were protected from a dose equivalent to 1,000 to 10,000 50% lethal doses (LD50) of BoNT/A when given three or four different anti-BoNT scFvs, each fused to an E-tag peptide, and an anti-E-tag IgG1 MAb. Toxin protection was enhanced when an scFv contained two copies of the E tag. Pharmacokinetic studies demonstrated that BoNT/A was rapidly cleared from the sera of mice given a pool of anti-BoNT/A scFvs and an anti-tag MAb but not from the sera of mice given scFvs alone or anti-tag MAb alone. The scFv pool and anti-tag MAb protected mice from lethality when administered up to 2 h following exposure of mice to a dose equivalent to 10 LD50 of BoNT/A. These results suggest that it will be possible to rapidly and economically develop and produce therapeutic antitoxins consisting of pools of tagged binding agents that are administered with a single, stockpiled anti-tag MAb.
机译:肉毒杆菌神经毒素(BoNT)和其他毒素的抗毒素是需要的,与具有大动物抗血清的常规疗法相比,它们可以经济地生产,具有改善的安全性和保质期。在这里,我们显示可以通过在小鼠体内施用表位标记的小蛋白结合剂以及单一抗标签单克隆抗体(MAb)来保护免受BoNT致死性和通过肝脏快速清除BoNT。在这项研究中使用的蛋白质结合剂是对BoNT血清型A(BoNT / A)具有高亲和力的单链Fv结构域(scFvs)。增加数量越来越多的不同标签的scFv协同增加了针对BoNT / A的保护水平。不需要任何BoNT / A结合剂具有毒素中和活性。当给小鼠三种或四种不同的抗BoNT scFv(分别与E标签肽和抗E标签IgG1融合)时,可保护其免受BoNT / A的1,000至10,000 50%致命剂量(LD50)剂量的伤害。单抗当scFv包含两个E标签副本时,毒素保护得到增强。药代动力学研究表明,给予抗BoNT / A scFvs和抗标签MAb的小鼠血清中BoNT / A迅速清除,但仅给予scFvs或单独使用抗标签MAb的小鼠血清中并未清除BoNT / A。当小鼠暴露于相当于10 LD50 BoNT / A的剂量后最多2小时给药时,scFv库和抗标签单抗可保护小鼠免于致死性。这些结果表明,将有可能快速,经济地开发和生产治疗性抗毒素,该治疗性抗毒素由标记的结合剂库组成,并与单一的储备式抗标记MAb一起施用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号